GENOME & CO.
Genome & Company is a biotechnology company that researches microbes and probiotics and develops dietary supplements, cosmeceuticals, and new drugs for obesity, diabetes, acne, atopic dermatitis, and cancer.
GENOME & CO.
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Status:
Active
Contact:
+82-31-628-0150
Total Funding:
1000 M KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Font Awesome Nginx Euro Microsoft Exchange Online Office 365 Mail Google Maps PHP
Current Employees Featured
Hansoo Park Chief Technology Officer & Co-Chief Executive Officer @ Genome & Co.
Chief Technology Officer & Co-Chief Executive Officer
Jisoo Pae Co-Founder & Chief Executive Officer @ Genome & Co.
Co-Founder & Chief Executive Officer
2015-09-01
Founder
Investors List
DSC Investment
DSC Investment investment in Venture Round - Genome & Co.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-08-10 | Scioto Biosciences | Genome & Co. investment in Series B - Scioto Biosciences | 26.5 M USD |
More informations about "Genome & Co."
Genome & Company
We consider customers, internal employees, business partners, shareholders, local community and all humanity as our stakeholders. Genome & Company improves the quality of life for customers by providing innovative new drugs. …See details»
Genome & Co. - Crunchbase Investor Profile
Genome & Co (G&C) is a microbiome based research and development company focused on researching microbes and probiotics.See details»
Genome & Company acquires US-based List Labs for $27 million
Sep 8, 2021 Genome & Company, Korea's leading microbiome anti-cancer drug developer, is set to expand its business scope to the contract development and manufacturing organization …See details»
Genome and Company (South Korea) Funding: $44.6M
Apr 24, 2025 Genome & Company is a clinical stage biotechnology company based in Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics …See details»
Genome & Company raises ₩54 bil. won via US subsidiary to fuel …
Apr 25, 2025 Genome & Company is cashing in on its U.S. subsidiary to bankroll its next phase of growth. The Korean biotech said Thursday it raised 54.1 billion won ($37.6 million) by …See details»
Genome & Co - Company Profile and News - Bloomberg Markets
Company profile page for Genome & Co including stock price, company news, executives, board members, and contact informationSee details»
Korea’s Genome & Company aims US CMO market
Sep 9, 2021 Genome & Company CEO Pae Jisoo South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into the globe. Genome & Company …See details»
Genome and Company: Revenue, Worth, Valuation & Competitors …
About Genome and Company Genome and Company is a Biotech related company founded in 2015 with 52 employees an estimated revenue of $8.1M, and. It has 10 competitors including …See details»
Genome & Company
Genome & Company is a global biopharmaceutical company that focuses on developing microbiome pharmaceuticals, consumer products and novel immune checkpoint inhibitors based on real-world clinical data and Multi-Omics …See details»
Genome & Co 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Genome & Co. Use the PitchBook Platform to explore the full profile.See details»
Genome & Company - Products, Competitors, Financials, …
About Genome & Company Genome & Company is a biopharmaceutical company specializing in the development of microbiome therapeutics and novel immune checkpoint inhibitors. The …See details»
Jisoo Pae님 - Genome & Company | LinkedIn
CEO at Genome and Company, a microbiome based research and development company… · ê²½ë ¥: Genome & Company · í•™ë ¥: Duke Fuqua School of Business · 지ì—: ëŒ€í•œë¯¼êµ Â· …See details»
The Company | Genome
The Company Positioned as a top financial consultancy firm, Genome is a UAE-based leading company dedicated to manage your business plans, progress, and profitability. Genome, …See details»
Native nucleosomes intrinsically encode genome organization
May 7, 2025 Analysis using various condensing agents or histone modifications and mutations indicates that the genome organization principle encoded into nucleosomes is mostly …See details»
Genome & Company
Genome & Company has established a new drug development platform, GNOCLE™ and effectively conduct research and development in innovative microbiome and novel target …See details»
ONTraC characterizes spatially continuous variations of tissue ...
May 8, 2025 Recent technological advances enable mapping of tissue spatial organization at single-cell resolution, but methods for analyzing spatially continuous microenvironments are …See details»
Advancing translational exposomics: bridging genome, exposome …
Apr 30, 2025 Understanding the interplay between genetic predisposition and environmental and lifestyle exposures is essential for advancing precision medicine and public health. The …See details»
Genome & Co. - Contacts, Employees, Board Members, Advisors
Genome & Co (G&C) is a microbiome based research and development company focused on researching microbes and probiotics.See details»
PtWAVE: a high-sensitive deconvolution software of sequencing …
Apr 29, 2025 Background Tracking of Insertions and DEletions (TIDE) analysis, which computationally deconvolves capillary sequencing data derived from the DNA of bulk or clonal …See details»
Regional and aging-specific cellular architecture of non-human …
Apr 28, 2025 These datasets greatly expand our knowledge of primate brain organization and highlight the potential involvement of specific molecular and cellular components in both the …See details»